The UOEHAssociation of Health Sciences J UOEH 24 (4):391-39S (2oo2) 391 (CaseReport) Abstract: Lithium addition to neuroleptic treatment brought about some improvement in 6 schizophrenic inpatients. in 3 of them, however, enhancement of daily activity did not parallel improvement in psychiatric symptoms.
Introduction
Lithium addition to neuroleptic treatment in schizophrenic patients may improve psychotic excitement, anxiety, depression and/or thought disorder [1, 2] , although several studies found no response with lithium augmentation [3] . Particularly, lithium may improve anxiety and depression in schizophrenic patients without any hyperactivity or manic symptoms [1] . Given the results of the recent meta-analysis showing no evidence that atypical antipsychotics are more effectiye than conventional antipsychotics [4] , lithium addition still deserves funher study.
On the other hand, to our knowledge, there has been no report suggesting that lithium affects the daily activity of schizophrenic patients.
ln the present preliminary study, we report 6 cases of lithium-treated schizophrenia. Lithium effects on daily activity and psychiatric symptoms are investigated.
Case Reports
One of the authors(A.S.)treated al1 6 patients consecutively, and assessed the changes in psychiatric symptoms and daily activity. Table 1 shows the patients' characteristics, lithium treatment, and the effbcts of such treatment on psychianic symptoms and daily activity. Of the 6 patients, 5 were female and 1 was male. Psychiatric diagnoses based on DSM-rv criteria were schizophrenia in 5 patients and schizoafifective disorder in 1 patient. He had suffered from schizophrenia for six years.
He had been on 9 mg per day of haloperidol and 200 mg per day of levomepromazine befbre On admission, she showed anxiety, auditory hallucination, delusion ef reference qnd depressive mood. After admission, sulpiride and mianserin were discontinued, and levomepromazine was increased to 80 mg per day. Three mg per day of haloperidol was added to the other psychotropics, and thereafter it was increased to 7.5 mg per day. Eight weeks after admission, 600 mg per day of lithium carbonate was added to the neuroleptics. Seven days later, anxiety, auditory hallucination and delusion of reference began to improve gradually. However, her daily activity remained unchanged(69% to 69%).
In total, as shown in Table 1 , daily activity was improved in 4 cases, unchanged in 1, and worsened in 1. 0n the other hand, depressive mood was improved in 3 patients, aggressiveness and autism were improved in 1 patient, and anxiety, auditory hallucinations and delusion of reference were improved in1patient. The other1patient remained unchanged.
Three of 6 patients(cases 1, 4 and 6)showed inconsistent responses with regard to psychiatric symptoms and daily activity. Also, Table 1 shows serum lithium levels measured 1 to 3 weeks after the starting of lithium.
Discussion
From our results, lithium addition was seen to be effective both for improving psychiatric symptoms arid for enhancing daily activity, although this was an open study with a small number of subjects.
Moreover, the method and duration of assessment of daily activity was limited. Interestingly, however, there was censiderable inconsistency of lithium responses with respect to psychiatric symptoms and daily activity. ' These findings suggest that daily activity as measured by the present method is not directly associated with psychiatric symptoms, and that the effects of lithium should also be assessed from the viewpoint of daily activity. 60： 
